病毒性肝炎合并糖尿病患者終末期肝病影響因素分析
中圖分類號(hào):R587.1;R512.6 文獻(xiàn)標(biāo)志碼:A DOI:10.3969/j. issn.1003-1383.2025.04.004
Analysis of influencing factors of end-stage liver disease in patients withviralhepatitiscombinedwith diabetesmellitus
LUO Yan 1 ,SONG Xiaolong',LI Nana’,MAO Yongkang 1 , LIU Dafeng 2 , ZHU Yanfeng 1? (1.School of Public Health,Chengdu Medical College,Chengdu 61o5OO,Sichuan,China; 2.Public Health Clinical Center ofChengdu,Chengdu 61oo61,Sichuan,China)
【Abstract】ObjectiveTo explore the influencing factorsof end-stageliverdisease(ESLD)in patients with viral hepatitiscombied with diabetes melltus,and toprovideabasisforthepreventionanddelayof disease progression inESD. MethodsClinicaldataof patientswithviral hepatitiscombinedwithdiabetesmelitusadmittedtoPublic Health Clinical Center of Chengdu from October 27,2O18 to January25,2022 were retrospectivelyanalyzed.Thepatients were divided into casegroupandcontrol groupbasedon whethertheysuffredfromESLD,andlogisticregressionanalysis wasused toidentify risk factors forESLD.ResultsUnivariateanalysisshowedthat gender,age,durationof viral hepatitis,whetherinsulin therapywasreceived,whetherantidiabeticdrugsweretaken,andtheclasificationofviralhepatitis were influencingfactors for ESLD( P<0.05 ).Afteradjusting the gender,the results of the multivariate logistic regresson analysis showed that older age ( OR=1.020 95% CI:1.011 - 1.030, P<0.05 ),longer duration of viral hepatitis ( OR=1.035 ,95% CI : 1. 024 - 1.045, P<0.05 ),and receiving insulin therapy( OR=1.261 ! 95% CI:1.040 - 1.528, P<0.05 )were independent risk factors for ESLD.Taking antidiabetic medications( OR=0.478 95% CI:0.383-0.596,P<0.05)was a protective factor forESLD.Patients withhepatitisChadalowerrisk of developing thediseasecomparedtothosewithhepatitisB( OR= 0.715, 95% CI:0.567 -0.901, P<0.05 ).ConclusionIn patients with viral hepatitis combined with diabetes mellitus, olderage,longerdurationofviralhepatitis,ndinsulintreatmentinhepatitisBpatientsareasociatedwithahigherriskof developing ESLD,while the use of hypoglycemic agents may help delay the progression of liver disease.
【Keywords】viral hepatitis; diabetes melitus;end-stage liver disease(ESLD);influence factors
終末期肝?。╡nd-stage liver disease,ESLD)是多種肝臟損傷引發(fā)的肝病晚期,包括慢加急性肝衰竭、肝硬化失代償、慢性肝衰竭以及肝細(xì)胞癌[1]。(剩余8179字)
-
-
- 右江醫(yī)學(xué)
- 2025年04期
- 負(fù)壓創(chuàng)面治療技術(shù)促進(jìn)糖尿病皮膚...
- 老年人內(nèi)在能力研究進(jìn)展...
- 大理地區(qū)呼吸道病原菌核酸檢測(cè)結(jié)...
- 病毒性肝炎合并糖尿病患者終末期...
- 基于孟德爾隨機(jī)化法探究宮頸(陰...
- 外周動(dòng)脈血?dú)夥治雎?lián)合aEEG監(jiān)...
- 替羅非班橋接阿替普酶靜脈溶栓治...
- 欽州市無償獻(xiàn)血者人類嗜T淋巴細(xì)...
- 非高密度脂蛋白/高密度脂蛋白比...
- 職業(yè)粉塵分別聯(lián)合噪聲、高溫暴露...
- 中國慢性病老年人疼痛和抑郁的關(guān)...
- 小檗堿治療糖尿病及其相關(guān)并發(fā)癥...
- 細(xì)胞分裂周期相關(guān)蛋白8在腫瘤中...
- 2型糖尿病合并代謝相關(guān)脂肪性肝...
- 母細(xì)胞性漿細(xì)胞樣樹突細(xì)胞腫瘤累...
- 自身免疫性膠質(zhì)纖維酸性蛋白星形...